Markey Trust Has Big Grants for Best

WASHINGTON-Robert J. Glaser has begun a five-year adventure in philanthropy to extend the frontiers of basic medical research in the United States. Only institutions doing the most innovative and important work need apply, but for those talented few scientists the sky’s the limit. Glaser is director for medical science at the Lucille P. Markey Charitable Trust, formed after the 1982 death of the owner of Calumet Farms, the Kentucky thorough-bred racing and breeding stable. She stipulate

Written byJeffrey Mervis
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Glaser is director for medical science at the Lucille P. Markey Charitable Trust, formed after the 1982 death of the owner of Calumet Farms, the Kentucky thorough-bred racing and breeding stable. She stipulated that within 15 years the Miami-based foundation must exhaust its endowment, expected to reach nearly $400 million, in support of basic medical research.

Last month the trust announced its largest round of grants. Eleven universities will receive $75 million over the next five years for new research programs, staff, major facilities and related activities. The University of California at San Francisco topped the list, with $13.7 million to reorganize its research and teaching programs to encourage interdisciplinary work in biology. $12.1 million each went to Yale University, for support of a program in molecular oncology and development, and Washington University, for a new center on the molecular biology of human disease. The trust also provides support for ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies